These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
471 related items for PubMed ID: 1713965
1. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance. Yaney GC, Stafford GA, Henstenberg JD, Sharp GW, Weiland GA. J Pharmacol Exp Ther; 1991 Aug; 258(2):652-62. PubMed ID: 1713965 [Abstract] [Full Text] [Related]
9. A comparison between the binding and electrophysiological effects of dihydropyridines on cardiac membranes. Hamilton SL, Yatani A, Brush K, Schwartz A, Brown AM. Mol Pharmacol; 1987 Mar; 31(3):221-31. PubMed ID: 2436031 [Abstract] [Full Text] [Related]
10. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. Zahradníková A, Minarovic I, Zahradník I. J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903 [Abstract] [Full Text] [Related]
11. Relationship of dihydropyridine binding sites with calcium-dependent neurotransmitter release in synaptosomes. Massieu L, Tapia R. J Neurochem; 1988 Oct; 51(4):1184-9. PubMed ID: 2458434 [Abstract] [Full Text] [Related]
12. Influence of Mg++ on the effect of diltiazem to increase dihydropyridine binding to receptors on Ca++-channels in chick cardiac and skeletal muscle membranes. Maan AC, Ptasienski J, Hosey MM. J Pharmacol Exp Ther; 1986 Dec; 239(3):768-74. PubMed ID: 2432217 [Abstract] [Full Text] [Related]
13. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. Nokin P, Clinet M, Beaufort P, Meysmans L, Laruel R, Chatelain P. J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036 [Abstract] [Full Text] [Related]
16. Dihydropyridine-sensitive Ca2+ channels: molecular properties of interaction with Ca2+ channel blockers, purification, subunit structure, and differentiation. Lazdunski M, Barhanin J, Borsotto M, Fosset M, Galizzi JP, Renaud JF, Romey G, Schmid A. J Cardiovasc Pharmacol; 1986 Nov; 8 Suppl 8():S13-9. PubMed ID: 2433514 [Abstract] [Full Text] [Related]
17. Modulation of L-type Ca2+ channels in clonal rat pituitary cells by membrane depolarization. Liu J, Bangalore R, Rutledge A, Triggle DJ. Mol Pharmacol; 1994 Jun; 45(6):1198-206. PubMed ID: 8022413 [Abstract] [Full Text] [Related]
18. Specific bindings of [3H](+)PN200-110 and [125I]omega-conotoxin to crude membranes from differentiated NG108-15 cells. Ichida S, Wada T, Nakazaki S, Matsuda N, Kishino H, Akimoto T. Neurochem Res; 1993 May; 18(5):633-8. PubMed ID: 7682662 [Abstract] [Full Text] [Related]
19. Binding Ca2+ to intracellular or to extracellular sites of dihydropyridine receptor of rabbit skeletal muscle discriminates between in vitro binding of Ca2+-channel agonist and antagonist. Kanngiesser U, Pongs O. Eur J Biochem; 1989 May 01; 181(2):467-73. PubMed ID: 2540975 [Abstract] [Full Text] [Related]
20. Voltage-dependent binding of dihydropyridine calcium channel blockers to guinea pig ventricular myocytes. Kamp TJ, Sanguinetti MC, Miller RJ. J Pharmacol Exp Ther; 1988 Dec 01; 247(3):1240-7. PubMed ID: 2849670 [Abstract] [Full Text] [Related] Page: [Next] [New Search]